NVI-100 / Nuvie Bio, Ferring - LARVOL DELTA

Emerging Clinical-Stage Neuroscience Company Nuvie Bio Announces Positive Phase 1 Data with its Lead Migraine Program (Businesswire) - P1 | N=NA | "Nuvie Bio...announced completion of a first-in-human trial with NVI-100, the company’s lead investigational drug for the acute treatment of migraine...The Phase 1 study in healthy volunteers has shown that NVI-100 is well-tolerated and achieves rapid, high and consistent plasma levels. Nuvie Bio plans to file an Investigational New Drug (IND) application for NVI-100 later this year, clearing the way for the start of its Phase 2 clinical trial...'The human pharmacokinetics data support that NVI-100 is the first CGRP receptor antagonist with the potential to deliver fast, high and consistent efficacy, which combined with the tolerability associated with this clinically validated mechanism of action, could profoundly transform the acute treatment of migraine.'"

IND • P1 data • Migraine